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Implications of Delayed Initiation of Radiotherapy
Accelerated Repopulation after Induction Chemotherapy for Stage III
Non-small Cell Lung Cancer
Chien P. Chen, MD, PhD,* Vivian K. Weinberg, PhD,† Thierry M. Jahan, MD,‡
David M. Jablons, MD,§ and Sue S. Yom, MD, PhD*
Introduction: For patients with stage III non-small cell lung cancer
treated with induction chemotherapy (ICT), delayed initiation of
subsequent radiotherapy (RT) may allow for repopulation in the
interval between treatment modalities and during the early phase of
RT. We quantified the impact of postinduction RT timing by
evaluating the pace of tumor regrowth.
Methods: Institutionally approved retrospective review identified
21 analyzable patients with stage III non-small cell lung cancer who
had platinum-based ICT followed by RT/ chemotherapy from
2002 to 2009. Radiographic response was determined by RECIST
criteria and the volume of the single largest tumor mass on the
pre-ICT, post-ICT, and RT-planning computed tomography scans.
Results: After ICT, the median percent volume change from pre-
ICT baseline was41% (range86 to86%). By the RT-planning
computed tomography scan, the median percent volume change
from the post-ICT timepoint was40% (range11 to311%) and
the median volume change was20 ml (range 4 to 102 ml); these
changes were significant (p  0.0002). Similar results were seen for
tumor diameter. A correlation was observed between the amount of
delay and degree of regrowth for percent volume (p  0.0006) and
percent diameter change (p  0.003). A delay greater than 21 days
produced greater increases in percent volume change (p  0.002)
and percent diameter (p  0.055) than lesser delays.
Conclusions: After ICT, tumor regrowth can occur within a few
weeks. Radiation treatment planning should begin as soon as pos-
sible after the administration of ICT to maximize the benefits of
cytoreduction.
Key Words: Stage III lung cancer, Induction chemotherapy, Radi-
ation, Repopulation.
(J Thorac Oncol. 2011;6: 1857–1864)
For patients with stage III non-small cell lung cancer(NSCLC), optimal treatment may include concurrent
chemoradiation (CRT) or preoperative chemotherapy or CRT
followed by an attempt at definitive surgical resection. For
certain stage III cases, induction chemotherapy (ICT) has
been theorized to provide the potential benefits of enhancing
resectability, testing chemosensitivity to a particular systemic
regimen, or reducing the tumor volume that must be treated
with high doses of radiation and thus reducing radiation-
related toxicity.
Early small randomized trials suggested a role for
perioperative ICT for stage III patients.1–3 A secondary anal-
ysis of RTOG 8804/8808 showed that for locally advanced
NSCLC treated with radiotherapy or chemoradiotherapy, ICT
was associated with a trend toward a survival benefit,4 espe-
cially for patients with nonsquamous histology. In a recent
phase II protocol of patients with stage III NSCLC, neoad-
juvant chemotherapy followed by chemoradiotherapy and
definitive surgery for stage IIIA bulky and selected IIIB
patients has so far demonstrated promising results.5,6 In the
early-stage NATCH trial, subgroup analyses showed that
patients with the highest stage disease included in the trial,
either stage II or T3N1, achieved nonsignificant but nominal
improvement in 5-year overall survival with neoadjuvant
chemotherapy compared with either surgery alone or surgery
with adjuvant chemotherapy, and more patients in the preop-
erative chemotherapy arm received all three cycles.7
It is important to note that randomized studies have
indicated that superior survival is achieved with concurrent
CRT rather than sequential chemotherapy and radiotherapy in
locoregionally advanced lung cancer.8–12 For eligible pa-
tients, upfront concurrent CRT should be considered first as
the accepted standard of care. However, the greater toxicity
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experienced during concurrent CRT may not make it the most
tolerable or most strategic choice for all patients.
Thus, particularly for patients who have an initially
marginal performance status, ICT may be used to decrease
the burden of locoregional disease to enable subsequent
definitive treatment or to identify patients harboring subclin-
ical distant metastasis for whom the toxicity of intensified
local treatment may not be justified. However, especially in
this population with marginal performance status, the prompt
initiation of subsequent definitive treatment may be delayed
because of various reasons, including recovery from post-ICT
toxicities, difficulty tolerating restaging procedures after ICT,
and logistical delays in the scheduling and start of radiother-
apy treatment. Unfortunately, post-ICT delays in initiating
subsequent therapy may result in accelerated tumor re-
growth.13 Regrowth of tumor and loss of the cytoreductive
advantages achieved from ICT may result in a greater pro-
pensity for treatment failure.14 A shorter overall treatment
package time is known to improve local control and survival
after radiotherapy in patients with lung cancer, especially if
cellular repopulation results in a local failure.15,16
For patients with stage III NSCLC who are considered
radiotherapy (RT) candidates after ICT, delays in RT initia-
tion may allow for accelerated repopulation in the interval
between modalities and during the early phase of RT. The
purpose of this study is to quantify the impact resulting from
delays in planning postinduction RT, as measured in terms of
tumor regrowth, in the setting of contemporary ICT regimens.
MATERIALS AND METHODS
Patient Population
Patients with locally advanced NSCLC who received
ICT and underwent computed tomography (CT) simulation in
preparation for thoracic RT given at the University of Cali-
fornia, San Francisco, between 2002 and 2009 were identified
for this retrospective investigation. These patients were eli-
gible for analysis if they received ICT before thoracic RT,
underwent three-dimensional CT-based simulation before
RT, and did not have surgical tumor resection after ICT or
before RT. Patients typically received ICT with the initial
intent of reducing tumor bulk to allow for a surgical resection
or to allow for safer radiotherapy delivery.
Thirty-one patients met initial criteria for inclusion, but
10 patients were excluded due to inadequately documented
clinical and radiographic data from the postinduction and
preradiotherapy periods. An institutional waiver of informed
consent (study 10-03691) was granted for retrospective re-
view of the medical records of these patients.
For the 21 patients included in this study, a staging
diagnostic CT scan with and without contrast was performed
before ICT was started, and a restaging diagnostic CT was
obtained after the last cycle of ICT. Subsequently, a radio-
therapy-planning CT was performed. All CT scans had a slice
thickness of no more than 3 to 5 mm.
Treatment Regimens
All but one patient received platinum-based ICT. The
most common regimen was carboplatin-paclitaxel for three
cycles. Other chemotherapy regimens included platinum-dou-
blets such as carboplatin-navelbine for three cycles, carbopla-
tin-gemcitabine for three cycles, and cisplatinum-etoposide
for two cycles. One patient received one cycle of single-agent
vinorelbine but because of toxicity was switched to single-
agent gemcitabine for four cycles. For those who were treated
with concurrent chemoradiotherapy after ICT, most patients
received a concurrent taxane, carboplatin-paclitaxel, or cis-
platinum-etoposide chemotherapy.
All patients except one received post-ICT thoracic RT
for curative intent. Fourteen (67%) patients received concur-
rent chemoradiotherapy after ICT, with the concurrent che-
motherapy regimens as described. Seven (33%) patients re-
ceived radiotherapy alone after ICT. The median prescribed
radiation dose was 6300 cGy (range 1400–7400 cGy), and
the mean prescribed dose was 5478 cGy.
Determination of Radiographic Response
For the purpose of this study, radiographic response
was determined by measuring the single largest tumor mass
both by largest diameter, per RECIST criteria, and volumetri-
cally.17 The delineation of the radiographically identified
tumor mass and the calculation of the volume of the tumor
mass were performed on CT scans using ADAC Pinnacle
8.0d (Madison, WI). Measurements were taken from the
pre-ICT, post-ICT, and RT-planning CT scans using the
standard lung level and window settings. Measurements were
performed by one observer (C.P.C.) and supervised for con-
sistency of procedures by a radiation oncologist experienced
in thoracic target delineation (S.S.Y.). Assuming a constant
growth rate, doubling time (DT) was estimated using the
Schwartz formula18:
DT  (t2  t1) ln 2/ln (VRT-planning/Vpostinduction)
whereby (t2  t1) represents the interval between the post-
ICT CT and the RT-planning CT.
Statistical Analysis
Descriptive statistics were calculated to summarize
patient and tumor characteristics. Nonparametric tests were
performed to evaluate change in measurements because of the
sample size and the possibility of non-normality. To analyze
the change in tumor volume and tumor diameter, the Wil-
coxon matched pairs test was applied. Spearman’s correlation
coefficients were calculated to explore the relationship be-
tween the interval between the postinduction restaging CT
and the planning CT scan with the percent change in tumor
volume and with the percent change in tumor diameter. The
Mann-Whitney U test was used to compare the distributions
of the percent change in the tumor volume and in the tumor
diameter for patients with delays of less than 21 days versus
21 days or longer in starting RT. All statistical calculations
were carried out using Statistica version 6.0 (StatSoft, Inc.,
Tulsa, OK). Significance was defined as a probability value
less than 0.05, and no adjustments were made for multiple
testing.
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RESULTS
Patient Demographics
Patient and tumor characteristics are summarized in
Table 1. The median age was 66 years, and the median
Karnofsky Performance Status score was 80. There were 15
(71%) stage IIIA and 6 (29%) stage IIIB patients. Clinical T
stages were 14% T1, 29% T2, 19% T3, and 38% T4 tumors.
Nodal stages were 14% N0, 10% N1, 62% N2, and 14% N3.
Various histologies were represented (52% squamous, 43%
adenocarcinoma, and 5% large cell).
Tumor Changes
Table 2 summarizes the median, minimum, maximum,
mean, and standard deviation for tumor volume and tumor
diameter measurements. The median pre-ICT tumor volume
and diameter were 80 ml (range 11.5–626 ml) and 5.7 cm
(range 2.7–11.0 cm), respectively. The median post-ICT
tumor volume and diameter were 48.9 ml (range 6.1–392.2
ml) and 4.1 cm (range 1.2–10.4 cm), respectively. Thus,
generally, a substantial cytoreductive response was seen in
response to ICT resulting in a median decrease of 19.8 ml
(range 253.6–60.6 ml) in volume and 1.0 cm (range
4.8–1.5 cm) in diameter. Sixteen patients experienced a
decrease in both tumor volume and diameter. However, with
a median interval between modalities of 21 days (range 3
to 176 days), the median tumor volume and diameter as
derived from the RT-planning CT regrew to 59.8 ml (range
6.8 –450 ml) and 5.7 cm (range 2.1–10.1 cm), respectively.
The median change in volume was 20 ml (range 4 to 102
ml) with a median change in diameter of 0.5 cm (range
0.3 to 2.1 cm).
Transitions from one therapeutic modality to another
are prone to delays for a variety of reasons. In our series,
delays in initiation of subsequent local therapy were caused
by logistical/scheduling constraints in 14 of 21 cases, but
there were also more complex issues such as planned surgical
intervention followed by a patient’s refusal of surgery (5/21
cases) and post-ICT-related toxicities or complications (2/21
cases). Figure 1 serves as an illustrative example of how
delays in initiation of subsequent local therapy can lead to
significant tumor repopulation after ICT. Figure 1A shows the
CT scan obtained before initiation of ICT given for a large
right-sided NSCLC tumor. Figure 1B shows the CT obtained
after ICT, demonstrating a notable radiographic response.
However, after a delay of 45 days, in Figure 1C, the tumor
size has increased, recovering 64% of the post-ICT volume
and 37% of the post-ICT tumor diameter as determined per
RECIST criteria.
To quantify the tumor response in terms of volume and
diameter from pre-ICT to post-ICT timepoints and the sub-
sequent tumor regrowth from post-ICT to the timepoint of the
RT-planning CT, we calculated the percent tumor volume
and diameter changes observed for these two intervals. Figure
TABLE 1. Patient and Tumor Characteristics
Gender
Male 11 (52%)
Female 10 (47%)
Age, median (range), yr 66 (52–86)
KPS, median (range) 80 (70–100)
Stage (IIIA 15, IIIB 6), n (%)
T1 3 (14)
T2 6 (29)
T3 4 (19)
T4 8 (38)
N0 3 (14)
N1 2 (10)
N2 13 (62)
N3 3 (14)
M0 21 (100)
Histology, n (%)
Squamous cell carcinoma 11 (52)
Adenocarcinoma 9 (43)
Large-cell carcinoma 1 (5)
Location of primary lung tumor, n (%)
RUL 6 (29)
RML 3 (14)
RLL 4 (19)
LUL 5 (24)
LLL 3 (14)
KPS, Karnofsky Performance Status; RUL, right upper lobe; RML, right middle
lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.
TABLE 2. Preinduction, Postinduction, and RT-Planning CT Tumor Size
Delay
Time (d)
Preinduction
Tumor
Volume (ml)
Postinduction
Tumor
Volume (ml)
RT-Planning
CT Tumor
Volume (ml)
Preinduction
Tumor
Diameter (cm)
Postinduction
Tumor
Diameter (cm)
RT-Planning
CT Tumor
Diameter (cm)
Median 21.0 80.0 48.9 59.8 5.7 4.1 5.7
Minimum 3.0 11.5 6.1 6.8 2.7 1.2 2.1
Maximum 176.0 626.2 392.2 450.0 11.0 10.4 10.1
Mean 31.8 117.7 77.0 102.2 6.0 4.7 5.5
SD 37.9 141.6 94.6 115.9 2.3 2.4 2.3
Delay time: time between postinduction chemotherapy CT scan and radiotherapy planning CT. Preinduction tumor volume: tumor volume of largest lesion (T) on preinduction
chemotherapy CT scan. Postinduction tumor volume: tumor volume of T on postinduction chemotherapy CT scan. RT-planning CT tumor volume: tumor volume of T on
postinduction chemotherapy CT scan. Preinduction tumor diameter: tumor diameter based on RECIST criteria of largest lesion (T) on preinduction chemotherapy CT scan.
Postinduction tumor diameter: tumor diameter based on RECIST criteria of T on postinduction chemotherapy CT scan. RT-planning CT tumor diameter: tumor diameter based on
RECIST criteria of T on postinduction chemotherapy CT scan.
RT, radiotherapy; CT, computed tomography; SD, standard deviation.
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2A presents the percent change in tumor volume post-ICT and
at RT-planning for each patient. Sixteen (76%) patients had a
reduction in tumor volume after ICT, whereas five (24%) had
stability or tumor progression. However, from the time of the
postinduction CT to the time of the RT-planning CT, 14
(87.5%) of the 16 patients who had shown a radiographic
response exhibited tumor regrowth, whereas 2 had disease
stability or a slight further decrease in tumor volume. Of the
five patients who had stability or tumor progression after ICT,
all five experienced tumor growth from the time of the
post-ICT restaging CT to the RT-planning CT (range 19–
57% regrowth). Similar trends were seen using the metric of
percent diameter change as illustrated in Figure 2B.
Figure 3 summarizes the median percent change with
ranges in the volume and diameter for these same intervals:
time from pre- to post-ICT RT scan and time from post-ICT
RT scan to RT-planning CT. The median percent change in
the tumor volume for these two intervals were 41% (range
86 to 86%) and 40% (range 11 to 311%), respectively.
Similarly, the median percent change in the tumor diameter
were 17% (range 63 to 27%) and 14% (range 3 to
172%). The Wilcoxon matched pairs test resulted in statisti-
cally significant differences in the tumor volume changes
from the pre-ICT to post-ICT CT scans (p 0.003) and from
the post-ICT to RT-planning CT scans (p  0.0002). Similar
trends for tumor diameter changes were observed (p  0.001
and 0.0002, respectively).
Tumor Change in Relation to Delay Time
To determine if tumor growth was related to an
increased interval time between the end of ICT and the
start of RT, Spearman correlation coefficients were calcu-
lated. Both the percent change in volume and percent
change in diameter were significantly correlated with the
interval delay (days) with correlation coefficients of 0.69
(p  0.0006) and 0.62 (p  0.003) for volumetric and
diameter changes, respectively.
Using the median duration between post-ICT and the
RT-planning CT, the study cohort was dichotomized with 12
patients having a duration 21 days and 9 patients having a
FIGURE 1. Tumor response and regrowth during interval between postinduction chemotherapy restaging CT scan and RT-plan-
ning CT. A, Preinduction chemotherapy CT of a large right-sided NSCLC tumor. B, Postinduction chemotherapy CT showing partial
response to ICT. C, RT-planning CT, obtained 45 days after postinduction chemotherapy restaging CT, illustrates tumor regrowth.
CT, computed tomography; RT, radiotherapy; NSCLC, non-small cell lung cancer; ICT, induction chemotherapy.
FIGURE 2. Percent change in tumor volume and tumor diameter. A, Tumor volume changes for each patient during two time
intervals. Light gray bars represent the percent volume change from pre-ICT to post-ICT. Dark gray bars are the percent volume
changes from post-ICT to the time of the RT-planning CT. B, The second figure summarizes percent change in diameter for each
patient during these two time intervals. ICT, induction chemotherapy; RT, radiotherapy; CT, computed tomography.
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duration 21 days. Figure 4 illustrates that for patients with
a delay duration of 21 days, there was a smaller percentage
tumor growth versus that seen in patients having more than
21 days of delay between the postinduction CT to the RT-
planning CT (median change in percent volume: 24 ml versus
34 ml and median change in percent diameter: 10 cm versus
35 cm). This cutpoint was found to result in a statistically
significant difference in the percent change in the tumor
volume and of borderline significance for the percent change
in the tumor diameter (p  0.002 for volume change and p 
0.055 for RECIST criteria). Figure 5 further illustrates the
relationship between delay in radiotherapy initiation and
tumor regrowth as a series of scatter plots.
Tumor Volume Doubling Time
To assess how fast the tumor volume increased from
post-ICT CT to the RT-planning CT, tumor volume DT were
calculated. All except two patients experienced a regrowth in
tumor volume, and the percent decrease in volume for these
two patients was 3 and 11%. The overall median DT was 44
days (range 18–668 days). The median tumor volume dou-
bling times for adenocarcinomas and squamous cell carci-
noma were 49 and 44 days, respectively. Given that the
median DTs were found to be on the order of weeks, it is of
no surprise that statistically significant tumor regrowth oc-
curred in a short interval after ICT, even for patients who had
a delay of 21 days between treatment modalities.
Tumor Response Based on Chemotherapy
Regimen
The various ICT regimens used in this study are sum-
marized in Table 3. For all induction regimens, the median
tumor change seemed to be a shrinkage of the tumor ranging
from a volume change of 20 to 42% and largest diameter
change of 6 to 44%. However, with median delays
ranging from 15 to 27 days, the tumor grew with a median
tumor volume change ranging from 12 to 45% and with a
median largest diameter change ranging from 9 to 17%. No
chemotherapy regimen seemed to be superior than another in
regards to the amount of tumor regrowth.
DISCUSSION
Delays during transition periods from one treatment
modality to another are known to lead to accelerated tumor
repopulation. In this study, we found that there was a statis-
tically significant regrowth even during what might be con-
sidered a relatively short transition interval of about 3 weeks.
Of note, this was true regardless of the ICT regimen, although
a caveat preventing more specific conclusions is the relatively
small sample size for each of the different regimens of
chemotherapy. In regards to tumor volume doubling time, our
results are consistent with findings found in previous stud-
ies.13 The median doubling time of 44 days is shorter than
that seen for untreated lung cancers, which is often greater
than 100 days,19 and this difference could suggest accelerated
repopulation in our cohort postinduction. We thus recom-
mend that for patients treated with ICT, the logistical process
of transition to RT treatment planning begin as soon as
possible after administration of the last planned chemother-
apy cycle to maximize the reduction in tumor burden. Within
the limits of medical tolerability, these results might also be
considered in future studies examining post-ICT tumor re-
population for patients being considered for surgery.
One consideration raised by this study is that treatment
delays due to transitions between modalities may mask po-
tential survival benefits that could be achieved from combi-
natorial approaches incorporating ICT. Meta-analyses of che-
motherapy have shown a 4 to 7% improvement in 2-year
FIGURE 3. Median percent change in tumor volume and
tumor diameter from pre-ICT to post-ICT CT scans and from
post-ICT to RT-planning CT scans. ICT, induction chemo-
therapy; CT, computed tomography; RT, radiotherapy.
FIGURE 4. Percent volume changes dichotomized by the
delay of the start of RT. Percent volume change, grouped
according to interval delay of 21 days or 21 days be-
tween postinduction chemotherapy CT scan and radiother-
apy planning CT. A significant difference was observed (p 
0.002). RT, radiotherapy; CT, computed tomography.
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survival when chemotherapy is added either neoadjuvantly or
concurrently with radiotherapy,20,21 and more particularly,
upfront concurrent chemoradiotherapy offers superior sur-
vival compared with sequential CRT approaches in locally
advanced NSCLC.10,12,22,23 However, in the sequential arms
of these studies, radiotherapy was started in a time period
ranging from 2 to 4 weeks after the completion of the ICT. As
shown in our study, patients who experienced a delay of 21
days or less between the completion of chemotherapy and
their radiotherapy-planning CT experienced less tumor re-
growth than those with an interval greater than 21 days. Even
minor delays in initiating locally directed treatment after ICT
might contribute to the inefficiency of the rendered treatments
and mute the cytoreductive benefits of ICT. Generally speak-
ing, the overall treatment package time has been shown to be
critical for outcomes in NSCLC and in other malignant
conditions such as head and neck cancer.24
Most of the studies comparing sequential versus con-
current chemoradiotherapy regimens have used conventional
daily radiotherapy regimens. However, altered-fractionation
radiotherapy may offer an alternative means of compensation
for the timing of radiotherapy initiation after ICT. In early
studies, continuous, hyperfractionated, accelerated radiother-
apy (CHART) decreased the overall treatment time to 12
consecutive days and improved outcomes when compared
with conventional radiotherapy regimens that required 6
weeks of treatment.25 However, these trials raised concern for
increased pulmonary toxicity when CHART occurred within
4 weeks after chemotherapy. Hence, subsequent trials incor-
porating ICT and CHART used a gap of at least 4 to 6
weeks.26 Although limited because of poor accrual, small
randomized trials have indicated that even with delays of 4 to
6 weeks between the completion of chemotherapy and initi-
ation of CHART, stage III patients treated with ICT followed
by CHART can achieve a median survival of greater than 20
months.26 Accelerated radiotherapy schedules could compen-
sate for the detrimental effects of an extended treatment
package time.
One limitation of our study was the small sample size.
The analysis was limited by the relatively small number of
FIGURE 5. Scatter plots illustrating the relationship of days between postinduction CT and planning RT scan to (A) percent
volume regrowth and (B) percent diameter change by RECIST criteria. Regression line is provided with R2 coefficient of deter-
mination to estimate proportion of variability accounted for by the model (superior fit when tumor changes are plotted by
RECIST criteria). CT, computed tomography; RT, radiotherapy.
TABLE 3. Summary of Induction Chemotherapy Regimens Used in this Study
Chemotherapy Cycles n
Pre-ICT to Post-ICT
(% Vol of Initial)
Post-ICT to RT CT
(% Vol of Post-ICT)
Pre-ICT to Post-ICT
(% RECIST of Initial)
Post-ICT to RT CT
(% RECIST Post-ICT) Delay (d)
Platinum
doublet w/
Taxanes 2–4 9 41.3 (80.2 to 86.4) 32.3 (10.6 to 92.8) 30.0 (50.23 to 24.0) 10.7 (2.9 to 41.2) 21 (8 to 53)
Gemcitabine 2–6 5 38.8 (86.2 to 34.9) 40.1 (2.6 to 133.9) 43.9 (63.4 to 13.5) 14.1 (1.0 to 172.1) 15 (3 to 176)
Etoposide 2 2 20.9 (42.8 to 1.03) 45.3 (39.6 to 51.0) 6.0 (16.5 to 4.5) 17.2 (9.1 to 25.2) 22 (21 to 23)
Othera 3–6 4 42.2 (71.5 to 50.8) 42.6 (7.6 to 310.6) 19.1 (43.1 to 27.0) 15.5 (5.1 to 103.0) 27 (2 to 49)
Other chemob 5 1 20.4 11.9 13.0 9.0 21
Pecent change in tumor size represented as median percent change with range indicated within parentheses.
a Platinum doublet with either pemetrexed or navelbine; combination involving sequential platinum doublets such as carbo-paclitaxel 2c followed by carbo-gemcitabine or such
as carbo-gemcitabine 3c followed by docetaxel 3c.
b Vinorelbine 1c followed by single agent gemcitabine 4c.
ICT, induction chemotherapy; RT, radiotherapy.
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patients treated in this manner at our institution. We restricted
our inclusion criteria to only this group of patients to keep the
analysis as clear as possible. A second limitation of our study
was that only the largest single tumor mass was measured,
such that a mixed response or aggregate response of all tumor
burden was not analyzed. The post-ICT responses of minor
areas of tumor involvement were not considered reasonable
to analyze or as clinically relevant as the response of the
dominant tumor mass. Therefore, we chose to focus on the
largest area of clearly measurable disease that could be
identified readily across all the scans. Although we did not
differentiate between primary or nodal disease progression,
we found that in only two cases was the dominant mass not
the primary lung tumor. The majority of the patients were
analyzed based on the response of bulky primary disease,
which we believe is a very relevant clinical end point.
However, a strength of our study’s measurement pro-
cedures was the use of both a volumetric measurement and
RECIST criteria; both were found to change dramatically in
relation to radiotherapy delay. For a well-demarcated spher-
ical tumor, changes in tumor size per RECIST criteria and
volumetric assessments are well correlated.27 However, be-
cause NSCLC tumors are often spiculated and asymmetric, a
volumetric approach may be more suitable to assess the
response of irregularly shaped tumors.28 Although RECIST is
a standard means of assessing response to systemic therapy,
it may not be sensitive enough to detect significant but
eccentric responses.
Another limitation of our study was the lack of
integration of functional imaging assessments. It was not
the standard of care during the time period covered by this
study to obtain positron emission tomography (PET) or
PET-CT scans for patients at each stage of their multimo-
dality therapy. It does remain unclear whether RECIST, or
any volumetric assessment, is superior to the prognostic
and therapeutic information obtained from other types of
imaging, especially in the era of PET and magnetic reso-
nance imaging.29–31
Finally, an area which will require further exploration
is quantification of the impact of radiographically determined
response on overall disease outcomes. Some studies indicate
that response to ICT does correlate with outcomes,32–36 but
other studies suggest that an early response to ICT has no
impact on survival.37 This question was beyond the scope of
our analysis but could be an interesting analysis to apply to
larger, better-controlled datasets. Certainly, from the perspec-
tive of radiation oncology, capitalizing on the radiographic
response to ICT in planning radiotherapy target volumes
should have some impact on reducing treatment-related tox-
icities such as pneumonitis or esophagitis; whether this would
be significantly affected by minimization of the delay in
transitioning to radiotherapy also remains an issue to be
defined more clearly in the future.
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